A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma
- Determine the maximum tolerated dose (MTD) of temozolomide using an extended continuous
schedule in combination with thalidomide in patients with advanced melanoma.
- Determine the response rate to this combination using an extended continuous schedule
at the MTD in 30 patients who have advanced metastatic melanoma without brain
metastases and in 15 patients who have metastatic melanoma in the brain.
- Further characterize the safety and toxicity of this combination in these patients.
OUTLINE: This is a dose escalation study of temozolomide (phase I) followed by a response
rate determination study (phase II).
Patients receive oral temozolomide daily for 6 weeks followed by 2-4 weeks of rest. Patients
receive oral thalidomide daily for the entire 8-10 week course. Treatment continues in the
absence of unacceptable toxicity or disease progression.
Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
patients experience dose limiting toxicities. Once the MTD is determined, additional
patients are accrued to receive treatment with temozolomide and thalidomide at the
recommended phase II dose.
PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for phase I and then an
additional 45 patients (15 with CNS disease, 30 without CNS disease) will be accrued for
phase II of this study within 18 months.
Primary Purpose: Treatment
Wen-Jen Hwu, MD, PhD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|